Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shionogi, Torii to Start Co-Promotion in September upon Takeover
Shionogi said on July 28 that it will launch a domestic co-promotion with Torii Pharmaceutical initially covering three products on September 1 in conjunction with the planned full integration of the Japan Tobacco (JT) subsidiary. The three products subject to…
To read the full story
Related Article
- Shionogi Eyes Faster QOL Biz Expansion with Ex-JT Researchers: CEO
February 2, 2026
- Shionogi Completes Takeover of JT’s Pharma Business
December 2, 2025
- Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
- Shionogi Completes Full Takeover of Torii under JT Deal
September 2, 2025
- Shionogi Clinches Tender Offer for Torii, Sets Stage for Full Takeover by September
June 20, 2025
- Shionogi to Buy Torii in 160 Billion Yen Deal, JT Pulls Plug on Pharma Biz
May 8, 2025
BUSINESS
- Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026
- Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
February 4, 2026
- Takeda, Kyoto University to End T-CiRA iPS Cell Program after 10 Years
February 4, 2026
- Fuji, Richter Expand Gynecology Partnership to Accelerate R&D
February 4, 2026
- Senju, Novartis Ink Promotion Tie-Up for Eye Drug Beovu in Japan
February 4, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…